A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients

Human Gene Therapy

Volumn 8, Issue 2, 1997, Pages 229-242

  Alvarez, Ronald D ^a   Curiel, David T ^b  

^a Dept of Obstetrics and Gynecology   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOGLOBULIN GENE; ONCOGENE NEU; OVARY CANCER; PHASE 1 CLINICAL TRIAL; REVIEW; VIRUS RECOMBINANT;

EID: 0031038574     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.2-229     Document Type: Review

References (49)

1. Boring, C., Squires, T., Tong, T. and Montgomery, S. Cancer statistics, 1994. CA - A Cancer Journal for Clinicians 44, 7-26 (1994).
2. Bloss, J.D., Liao, S.-Y., Buller, R.E., Manetta, A., Berman, M.L., McMeekin, S., Bloss, L.P. and DiSaia, P.J. Extraovarian peritoneal serous papillary adenocarcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 50, 347-351 (1993).
3. Ozols, R. and Young, R. Chemotherapy of ovarian cancer. Semin Oncol 11, 251 (1984).
4. Omura, G., Blessing, J., Ehrlich, C., Miller, A., Yordan, E., Creasman, W. and Homesley, H. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group study. Cancer 57, 1725-1730 (1986).
5. Neijt, J.P., van der Burg, M.E.L., Vriesendorp, R., van Lindert, A.C.M., van Lent, M. Ten Bokkel Huinink, W.W., van Oosterom, A.T., Kooyman, C.D., Hamerlynck, J.V.T.H., van Houwelingen, J.C. and Pinedo, H.M. Randomized trial comparing combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2, 594-600 (1984).
6. Decker, D., Fleming, T., Malkasian, G., Webb, M., Jeffries, J. and Edmonson, J. Cyclophosphamide plus cis-platinum in combination: Treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 60, 481 (1982).
7. McGuire, W., Hoskins, W., Brady, M., Kucera, P.H., Look, K.Y., Partridge, E.E. and Davidson, M. A phase III trial comparing cisplatin/cytoxan (CC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proceedings Am Soc Clin Oncol 12(Abstract 808), 255 (1993).
8. McGuire, W.P. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 51(1), 78-85 (1993).
9. Vergote, I., Himmelman, A., Frankendal, B., Scheistroen, M., Vlachos, K. and Trope, C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47, 282-286 (1992).
10. Sutton, G.P., Blessing, J.A., Hornesly, H.D., Berman, M.L. and Malfetano, J. Phase II trail of ilosfamide and mesna in advanced epithelial ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7, 1672-1676 (1989).
11. Markman, M. Current status of intraperitoneal therapy for ovarian cancer. Curr Opinion Obstet Gynecol 5, 99-104 (1993).
12. Thomas, G.M. and Dembo, A.J. Integrating radiation therapy into the management of ovarian cancer. Cancer 71, 1710-1718 (1993).
13. Rosenberg, S.A., Anderson, W.F., Blaese, M., Hwu, P., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Ettinghausen, S.E., Parkinson, D.N. and White, D.E. The development of gene therapy for the treatment of cancer. Annals of Surgery 218, 455-164 (1993).
14. Karp, J.E. and Broder, S. New directions in molecular medicine. Cancer Research 54, 653-665 (1994).
15. Gutierrez, A.A., Lemoine, N.R. and Sikora, K. Gene therapy for cancer. The Lancet 339, 715-721 (1992).
16. Lemoine, N. and Sikora, K. Interventional genetics and cancer treatment. BMJ 306, 665-666 (1993).
17. Vanchieri, C., Opportunities "opening up" for gene therapy. JNCI 85, 90-91 (1993).
18. Freeman, S.M. and Zwiebel, J.A. Gene therapy of cancer. Cancer Investigation 11, 676-688 (1993).
19. Dorudi, S., Northover, J.M.A. and Vile, R.G. Gene transfer therapy in cancer. Br J Surg 80, 566-572 (1993).
20. Sikora, K. Gene therapy for cancer. Tibtech 11, 197-201 (1993).
21. Krol, A.V., Mol, J.N.M. and Stuitje, A.R. Modulation of eukaryoutic gene expression by complement RNA or DNA sequences. Biotechniques 6, 958-976 (1988).
22. Helene, C. and Toulme, J.-J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochemica et Biophysica 1049, 99-125 (1990).
23. Zon, G. Oligonucleotide as potential chemotherapeutic agents. Pharmaceutical Research 5, 539-549 (1988).
24. Stein, C.A. and Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magic? Science 261, 1004-1012 (1993).
25. Kashani-Sabet, M., Funato, T., Florenes, V.A., Fodstad, O. and Scanlon, K.J. Suppression of a neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Research 54, 900-902 (1994).
26. Wickstrom, E.L., Bacon, T.A., Gonzalez, A., Freeman, D.L., Lyman, G.H. and Wickstrom, E. Human promelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 85, 1028-1032 (1988).
27. Georges, R.N., Mukhopadhyay, T., Zhang, Y., Yen, N. and Roth, J.A. Prevention of orthotopic human lung cancer growth by intratrachela instillation of a retroviral antisense k-ras construct. Cancer Research 53, 1743-1746 (1993).
28. Ratahczak, M.A., Kant, J.A., Luger, S.M., Hijiya, N., Zhang, J., Zon, G. and Gerwitz, A.M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligonucleotides. Proc Natl Acad Sci USA 89, 11823-11827 (1992).
29. Iverson, P.L., Zhu, S., Meyer, A. and Zon, G. Cellular uptake and subcellular distribution of phosphorothioate into cultured cells. Antisense Research and Development 2, 211-222 (1992).
30. Bergan, R., Connell, Y., Fahmy, B. and Neckers, L. Electroporation enhance c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Research 21, 3567-3573 (1993).
31. Citro, G., Perrotti, D., Cucco, C., D'Agnano, I., Sacchi, A., Zupi, G. and Calabretta, B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89, 7031-7035 (1992).
32. Seemayer, T.A. and Cavenee, W.K. Biology of disease - Molecular mechanisms of oncogenesis. Laboratory Investigation 60, 585-599 (1989).
33. Duke, R.C. and Cohen, J.J. Morphological and biochemical assays of apoptosis. Current Protocols Supplement 3 (1992).
34. Bertram, J., Killian, M., Brysch, W., Schlingensiepen, K.-H. and Kneba, M. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochemical and Biophysical Research Communications 200, 661-667 (1994).
35. Brysch, W., Magal, E., Louis, J.-C., Knust, M., Klinger, I. and Schlinggensiepen, R. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Therapy 1, 99-105 (1994).
36. Vaux, D.L. Toward an understanding of the molecular mechanisms of physiologic cell death. Proc Natl Acad Sci USA 90, 786-789 (1993).
37. Williams, G.T. Programmed cell death: apoptosis and oncogenesis. Cell 65, 1097-1098 (1991).
38. Mishell, B.B., Shiigi, S.M., Henry, C., Chan, E.L., North, J., Gaillily, R., Slomich, M., Miller, K., Marbrook, J., Parks, D. and Good, A.H. Preparation of mouse cell suspensions, Selected Methods in Cellular Immunology 21-22 (1980).
39. Deshane, J., Loechel, F., Corny, R.M., Siegal, G.P., King, C.R. and Curiel, D.T. Intracellular single-chain antibody directed against erbB2 down regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy 1, 332-337 (1994).
40. Setoguchi, Y., Jaffe, H.A., Chu, C.-S. and Crystal, R.G. Intraperitoneal in vivo gene therapy to deliver alpha1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10, 369-377 (1994).
41. Smythe, W.R., Kaiser, L.R., Hwang, H.C., Amin, K.M., Pilewski, J.M., Eck, S.J., Wilson, J.M. and Abelda, S.M. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57, 1395-1401 (1994).
42. Yarden, Y. and Ullrich, A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 57, 443-478 (1988).
43. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G. and Keith, D.E. Studies of the HER-2/neu proto-oncogene in the human breast and ovarian cancer. Reports, 707-712 (1989).
44. Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R. and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115 (1988).
45. Hudziak, R.M., Schlessinger, J. and Ulrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84, 7159-7163 (1987).
46. Giovanella, B.C., Vardeman, D.M., Williams, L.J., Taylor, D.J., Deipolyi, P.D., Greef, P.J., Stehlin, J.S., Ullrich, A., Cailleau, R., Slamon, D.J. and Gary, H.E. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of HER-2/Neu oncogene. Int J Cancer 47, 66-71 (1991).
47. Hynes, N.E. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biology 4, 19-26 (1993).
48. Braly, P., Doroshow, J. and Hoff, S. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol Oncol 25, 319-333 (1986).
49. Jenkins, J., Sugarbaker, P.H., Gianla, F.J. and Myers, C.E. Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154, 858-864 (1982).